Key Figures Q3 2019

SEK m, unless otherwise stated

2019

Jul-Sep

2018

Jul-Sep

2019

Jan-Sep

2018
Jan-Sep

12 mth       
Oct 2018-
Sep 2019

12 mth
Oct 2017-
Sep 2018

Net revenues

231.2

216.6

606.7

556.0

833.9

747.0

whereof Zubsolv® US net revenues

182.7

165.4

528.8

454.9

695.4

581.4

Cost of goods sold

-25.9

-42.4

-82.5

-128.4

-125.9

-178.7

Operating expenses

-99.4

-139.6

-364.5

-369.4

-510.7

-480.0

EBIT

105.9

34.6

159.7

58.2

197.4

88.2

EBIT margin, %

45.8

16.0

26.3

10.5

23.7

11.8

US EBIT

93.4

55.6

252.7

136.4

314.5

156.2

US EBIT margin, %

51.1

33.6

47.8

30.0

45.2

26.9

EBITDA

114.1

39.8

186.3

73.7

229.3

109.0

Earnings per share, before dilution, SEK

3.22

1.80

5.21

2.50

6.66

3.27

Earnings per share, after dilution, SEK

3.16

1.77

5.10

2.46

6.54

3.26

Cash flow from operating activities

135.7

24.5

230.7

170.4

302.5

147.4

Cash and cash equivalents

812.9

516.6

812.9

516.6

812.9

516.6

 

Distribution of Net Revenues Q3 2019

SEK m

2019

Jul-Sep

2018

Jul-Sep

2019

Jan-Sep

2018
Jan-Sep

12 mth

Oct 2018-
Sep 2019

12 mth

Oct 2017-
Sep 2018

Zubsolv® US

182.7

165.4

528.7

454.9

695.4

581.4

Zubsolv - ex US

0.0

0.2

0.1

31.0

5.3

36.6

Zubsolv – total

182.7

165.6

528.8

485.9

700.7

618.0

Abstral® royalties

42.4

48.7

66.3

66.4

118.7

121.8

Edluar® royalties

6.1

2.3

10.2

3.7

13.1

7.3

OX-MPI

0.1

-

1.4

-

1.4

-

Total

231.2

216.6

606.7

556.0

833.9

747.1

Cash flow Q3 2019

SEK m

 

2019

Jul-Sep

 

2018

Jul-Sep

 

Jan - Sep

2019

Jan - Sep

2018

12 months

Oct 2018 -
Sep 2019

Cash flow from operating activities

135.7

24.5

230.7

170.4

302.5

Investment activities

-14.5

-0.5

-15.3

-2.2

-19.2

Financing activities

-36.9

-0.1

-49.4

0.0

-49.4

Cash flow (excl exchange rate differences)

84.3

23.9

166.0

168.2

233.8

Liquid funds

812.9

516.6

812.9

516.6

812.9